BioCentury | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

...drug discovery and clinical research. Eyevensys planning ocular gene therapy trial with $30M B round Eyevensys S.A.S....
...this year its aiSLE DX biomarker assay for early prediction of lupus flares. BioCentury Staff Airway Therapeutics LLC Eyevensys S.A.S. Intra-Cellular...
BioCentury | Dec 12, 2017
Company News

Management tracks: Achaogen, Minerva

...Interim CFO Jeffrey Whitnell resigned. The company is seeking a principal financial officer. Ophthalmic company Eyevensys S.A.S....
BioCentury | Sep 14, 2017
Company News

Management tracks: SymCel, Taro, Akcea

...an information technology security company acquired by Hitachi Systems Security Inc. (Irvine, Texas). Ophthalmic company Eyevensys S.A.S....
...search for a principal financial officer. Jennie Walters Aeterna Zentaris Inc. Akcea Therapeutics Inc. Artios Pharma Ltd. AstraZeneca plc Biogen Inc. BioLamina AB Eyevensys S.A.S. Intellipharmaceutics...
BioCentury | Sep 19, 2016
Financial News

Eyevensys financial update

...Eyevensys S.A.S. , Paris, France Business: Ophthalmic Date announced: 2016-09-15 Note: Eyevensys raised an undisclosed amount...
BioCentury | Dec 3, 2015
Product R&D

Eyeing fewer needles

...delivery than the ophthalmic therapies that have entered the market in the last 10 years. Eyevensys...
...is also developing an anti-VEGF gene therapy to compete with Lucentis and Eylea. However, while Eyevensys'...
...because its approach offers a "number of key advantages over the other alternative therapeutic strategies." Eyevensys'...
BioCentury | Oct 19, 2015
Financial News

Eyevensys completes venture financing

Eyevensys S.A.S. , Paris, France Business: Ophthalmic Date completed: 2015-10-09 Type: Venture financing Raised: EUR7.5 million ($8.5 million) Investors: Boehringer Ingelheim Venture Fund; Bpifrance ; CapDecisif; Inserm Transfert WIR Staff...
BioCentury | Apr 22, 2013
Company News

Eyevensys board of directors update

Eyevensys S.A.S. , Paris, France Business: Ophthalmic Appointed: Michel Pairet, head of non-clinical R&D at Boehringer Ingelheim GmbH WIR Staff Ophthalmic...
BioCentury | Apr 22, 2013
Financial News

Eyevensys completes venture financing

Eyevensys S.A.S. , Paris, France Business: Ophthalmic Date completed: 4/11/13 Type: Venture financing Raised: Not disclosed Investors: Boehringer Ingelheim Venture Fund WIR Staff...
BioCentury | Apr 1, 2013
Company News

Eyevensys management update

Eyevensys S.A.S. , Paris, France Business: Ophthalmic Hired: Ivan Cohen-Tanugi as CEO, formerly VP and general manager of the biologics and specialty unit at Teva Pharmaceutical Industries Ltd. WIR Staff Ophthalmic...
BioCentury | Feb 13, 2012
Finance

Ventech reinvention

...€3 million ($3.9 million) and invested in 10 companies, including French gene therapy ophthalmic play Eyevensys S.A.S....
Items per page:
1 - 10 of 12
BioCentury | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

...drug discovery and clinical research. Eyevensys planning ocular gene therapy trial with $30M B round Eyevensys S.A.S....
...this year its aiSLE DX biomarker assay for early prediction of lupus flares. BioCentury Staff Airway Therapeutics LLC Eyevensys S.A.S. Intra-Cellular...
BioCentury | Dec 12, 2017
Company News

Management tracks: Achaogen, Minerva

...Interim CFO Jeffrey Whitnell resigned. The company is seeking a principal financial officer. Ophthalmic company Eyevensys S.A.S....
BioCentury | Sep 14, 2017
Company News

Management tracks: SymCel, Taro, Akcea

...an information technology security company acquired by Hitachi Systems Security Inc. (Irvine, Texas). Ophthalmic company Eyevensys S.A.S....
...search for a principal financial officer. Jennie Walters Aeterna Zentaris Inc. Akcea Therapeutics Inc. Artios Pharma Ltd. AstraZeneca plc Biogen Inc. BioLamina AB Eyevensys S.A.S. Intellipharmaceutics...
BioCentury | Sep 19, 2016
Financial News

Eyevensys financial update

...Eyevensys S.A.S. , Paris, France Business: Ophthalmic Date announced: 2016-09-15 Note: Eyevensys raised an undisclosed amount...
BioCentury | Dec 3, 2015
Product R&D

Eyeing fewer needles

...delivery than the ophthalmic therapies that have entered the market in the last 10 years. Eyevensys...
...is also developing an anti-VEGF gene therapy to compete with Lucentis and Eylea. However, while Eyevensys'...
...because its approach offers a "number of key advantages over the other alternative therapeutic strategies." Eyevensys'...
BioCentury | Oct 19, 2015
Financial News

Eyevensys completes venture financing

Eyevensys S.A.S. , Paris, France Business: Ophthalmic Date completed: 2015-10-09 Type: Venture financing Raised: EUR7.5 million ($8.5 million) Investors: Boehringer Ingelheim Venture Fund; Bpifrance ; CapDecisif; Inserm Transfert WIR Staff...
BioCentury | Apr 22, 2013
Company News

Eyevensys board of directors update

Eyevensys S.A.S. , Paris, France Business: Ophthalmic Appointed: Michel Pairet, head of non-clinical R&D at Boehringer Ingelheim GmbH WIR Staff Ophthalmic...
BioCentury | Apr 22, 2013
Financial News

Eyevensys completes venture financing

Eyevensys S.A.S. , Paris, France Business: Ophthalmic Date completed: 4/11/13 Type: Venture financing Raised: Not disclosed Investors: Boehringer Ingelheim Venture Fund WIR Staff...
BioCentury | Apr 1, 2013
Company News

Eyevensys management update

Eyevensys S.A.S. , Paris, France Business: Ophthalmic Hired: Ivan Cohen-Tanugi as CEO, formerly VP and general manager of the biologics and specialty unit at Teva Pharmaceutical Industries Ltd. WIR Staff Ophthalmic...
BioCentury | Feb 13, 2012
Finance

Ventech reinvention

...€3 million ($3.9 million) and invested in 10 companies, including French gene therapy ophthalmic play Eyevensys S.A.S....
Items per page:
1 - 10 of 12